ESTA · Establishment Labs Holdings Inc.
$63.04
-1.13 (-1.76%)
At close · Oct 1
Return incl. dividend (before tax)
Market Cap
$1.97B
Shares
29.80M
Volume · Oct 1
388.62K
Avg daily vol (3M)
452.11K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$64.17
Open$64.02
Day$62.72–64.43
52W close$38.94–95.65
Avg vol 30d348K
Short int4.4M · 14.7% float · 12.8d
Short vol65%
Last earningsAug 6, 2026
DataJan 2020–Sep 2026
Filing10-Q · Aug 7
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 5 wks
filed Aug 7, 2026
call held May 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$245.82M
Trailing 12 months
Net income (TTM)
−$38.89M
Trailing 12 months
Revenue growth YoY
+31.7%
Year over year
Operating margin
-7.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-2.1%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+4.2%
Year over year · more shares
Price change (1Y)
+56.6%
Trailing year
Short interest
14.7%
Latest settlement · 12.8 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Bullish
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 16.4 · calm
Equity put/call 0.57
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−12%
below
Price vs 50-day avg
−16%
below
RSI (14)
33
neutral
MACD trend
Negative
52-week position
44%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−8%
trailing
6-month return
+3%
trailing
YTD return
−12%
this year
Relative strength
−9%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $76 › 200d $73 — 50d above 200d
Institutional flow
Accumulating
+11% holders QoQ · +55 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
14.72% of float · ▼ -0.2% MoM · 12.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
198 holders — near 3-yr high, broad support
Squeeze score
62
elevated · 0–100
Fundamentals
Revenue growth
+76%
Y/Y
Gross margin
239%
contracting
EPS growth
+43%
Y/Y
Free cash flow
$-56.9M
Balance sheet
$90.3M
net cash
Quant / Vol
risk profile
Volatility
54%
annualized · 1-yr
Max drawdown
−33%
past year
ATR
4.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 6, 2026
Full-year revenue guidance
· full year 2026
Initiated
$269M – $271M
prior FY $211.08M
midpoint +27.9% Y/Y
Guided vs delivered
· last 6 settled
Worldwide revenue
2024
guided $174M – $184M
$166.03M
Miss −7.2%
2023 revenue guidance
2023
guided $165M
$165.15M
Beat +0.1%
Full-year guidance
2022
guided $155M – $165M
$161.7M
In line
Annual sales guidance
2021
guided $124M – $128M
$126.68M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−12%
Bearish
Price vs 50-day avg
−16%
Bearish
RSI (14)
33
Neutral
MACD trend
Negative
Bearish
52-week position
44%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $76 › 200d $73 — 50d above 200d
Institutional flow
Accumulating
+11% holders QoQ · +55 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
14.72% of float · ▼ -0.2% MoM · 12.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
198 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $39
Now $64 · 44%
Range high $96
vs 200-day avg -12%
vs 50-day avg -16%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ESTA
this stock
Establishment Labs Holdings Inc.
|
$1.97B | -12.0% | +76.5% | — | 14.7% |
|
ABT
Abbott Laboratories
|
$174.90B | -21.1% | +5.7% | 28.1 | 1.1% |
|
MDT
Medtronic plc
|
$113.38B | -10.2% | +8.4% | 21.8 | 1.3% |
|
SYK
Stryker Corp
|
$104.47B | -21.6% | +11.2% | 28.2 | 2.0% |
|
BSX
Boston Scientific Corp
|
$63.59B | -54.2% | +12.5% | 17.8 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ESTA | -5.3% | -7.7% | +3.4% | -7.4% | -12.0% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | -4.6% | -7.9% | -8.8% | -6.9% | -23.8% |